Network Version
Cevipabulin Data Sheet
| Product Name: | Cevipabulin |
 |
|---|---|---|
| CAS No.: | 849550-05-6 | |
| Cat. No.: | HY-14949 | |
| MWt: | 464.82 | |
| Formula: | C18H18ClF5N6O | |
| Purity : | >98% | |
| Solubility: | DMSO : 16.67 mg/mL (35.86 mM; Need ultrasonic) | |
| Mechanisms: | Target: Cancer | |
| Biological Activity: | ||
|
Cevipabulin (TTI-237) is an oral, microtubule-active antitumor compound and inhibits the binding of [3H] vinblastine to tubulin, with an IC50 of 18-40 nM for cytotoxicity in human tumor cell line[1][2].
IC50 & Target:IC50: 18-40 nM (microtubule in human tumor cells)[1].
In Vitro: Cevipabulin (0-50 nM, 72 hours) shows good activity (between 18 and 40 nM IC50 values) on cell lines from ovarian, breast, prostate, and cervical tumors[1]. Flow cytometry experiments reveal that, Cevipabulin (TTI-237) at low concentrations (20-40 nM) produces sub-G1 nuclei and, at concentrations above 50 nM, it causes a strong G2-M block[1]. In Vivo: Cevipabulin (TTI-2370)( 5, 10, 15, and 20 mg/kg, every 4 days for 4 cycles, in mice) is active by i.v. and p.o. administration against human tumor xenografts, showing dose-dependent effects, with good antitumor activity at 20 and 15 mg/kg[1]. |
||
1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA
Tel: 609-228-6898 Fax: 609-228-5909 Email: [email protected] Web:www.medchemexpress.com